

Medical Device Regulatory Science
Else Kröner Fresenius Center for Digital Health

***'Status quo' AI Regulation: Frameworks and
Implications for Healthcare:
Focus 'device thinking' and focus 'Europe'***


Disclosures (3 years)

COMPANIES:

- Ada Health GmbH (ongoing)
- Flo Ltd (ongoing)
- haleyon plc (2025 – 2026)
- AMBOSS SE (2026)

GOVERNMENT

- Expert Advisor: European Commission Directorate General Research & Innovation and SANTE (2025)
- Expert Advisor: Saudi Arabia FDA (2025 & 2026)



Prof. Dr. Stephen Gilbert

Professor of Medical Device
Regulatory Science, Else Kröner
Fresenius Center for Digital Health,
Faculty of Medicine Carl Gustav
Carus, TUD Dresden University of
Technology

Faculty of Business and Economics,
TUD Dresden


10:45 - 12:15 (90 mins)

10:45 - 11:25:	Regulation of medical devices
11:25 - 11:30	Questions: regulation of medical devices
11:30-12:10	Regulation of LLMs, GenAI, Agents
12:10-12:15	Questions: regulation of LLMs, GenAI, Agents

Professor, researcher, key opinion leader - medical device / IVD regulation, RegTech, AI in medicine regs



Prof. Dr. Stephen Gilbert, Professor of Medical Device Regulatory Science



Why regulatory science one of the biggest questions of this decade and the next?


“[the EU is caught in a middle technology trap ... over / over complex regulation is a large part of the problem and this is an existential threat to the future of EU competitiveness]”



The societal role of the AI regulatory scientist ...

"The antichrist comes to power by talking constantly about Armageddon, about rumours of wars and scaring you into giving him control over science and technology,"

Peter Thiel, 2025 (owner of / investor in of some of the world's biggest technology companies)



Themes


1. What is a 'medical device'?
2. Why are medical devices regulated?
3. How are medical devices regulated?
4. Why regulate AI at all?
5. Why regulate AI as a 'medical device'?
6. How is AI regulated as a device in the EU?
7. Some challenges with regulating AI as a 'device'
8. Some new approaches in regulation
9. Some even bigger in regulating newer AI as a 'device'
10. Some differences between US and EU regulation of AI – and who is 'right'?
11. Some interesting US approaches



Dresden
University of
Technology

What is a medical device?

What is a medical device?



What is a medical device?

...a thing intended for:

- diagnosis, prevention, monitoring, prediction, prognosis, treatment or alleviation of disease / compensation for injury
- investigation, replacement or modification of the anatomy or of a physiological or pathological process or state,
- information by means of in vitro examination of specimens



What is an IVD? ...a thing...

- including - any medical device which is a reagent, reagent product, calibrator, control material, kit, instrument, apparatus, piece of equipment, software or system
- **intended by the manufacturer** to be used in vitro for the examination of specimens, including blood and tissue donations, derived from the human body, solely or principally for the purpose of providing information ... **by means of in vitro examination of specimens**






Dresden
University of
Technology

What is the status quo regulation of medical devices?

Medical Device Regulatory Science



Prof. Dr. Stephen Gilbert

Professor of Medical
Device Regulatory
Science

Else Kröner Fresenius
Center for Digital
Health

TUD Dresden
University of
Technology

What is (the) medical device regulation?

" ...aims to **ensure the smooth functioning of the internal market as regards medical devices**, taking as a base a high level of protection of health for patients and users, and taking into account the small- and medium-sized enterprises that are active in this sector. ...objectives ...not being secondary to the other."

5.5.2017

EN

Official Journal of the European Union

L 117/1

I

(Legislative acts)

REGULATIONS

REGULATION (EU) 2017/745 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL



of 5 April 2017

on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC


(Text with EEA relevance)

THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION,

What is (the) medical device regulation?




What is (the) medical device regulation?



'regulatory AFFAIRS'

- "MDR says x – you must ..."
- "Have you done ...?"
- "Have you followed ISO#####:#####...?"
- "Is your evidence for performance of the device good enough to show?"
- "I will not sign document x until you do y."



'regulatory SCIENCE'

- What is the evidence this regulation produces better outcomes...?
- What alternative ways of regulating are there...?
- What are the unintended outcomes...?
- What regulatory approach is needed for new technology x...?
- Can this regulation be delivered safely but automated, faster?




***Why do we need medical device regulation?:
Was MDR/IVDR necessary?***

The problem...



The problem.... Is regulation necessary?



"I don't want to have a ticking time bomb inside me"

– PIP breast implant recipient

ICIJ INTERNATIONAL CONSORTIUM
of INVESTIGATIVE JOURNALISTS



DePuy metal-on-metal hip implants

- agreed to pay \$4 billion
- 8000 lawsuits

The problem Is regulation necessary?

Update: Certain [REDACTED] Ventilators, BiPAP Machines, and CPAP Machines Recalled Due to Potential Health Risks: FDA Safety Communication

Since April 2021 through April 30, 2022, the FDA received more than 21,000 MDRs, including 124 reports of death, associated with the PE-PUR foam breakdown or suspected foam breakdown. The MDRs received included both mandatory reports from [REDACTED] and voluntary reports from health professionals, consumers, and patients. A wide range of injuries have been reported in these MDRs, including cancer, pneumonia, asthma, other respiratory problems, infection, headache, cough, dyspnea (difficulty breathing), dizziness, nodules, and chest pain.

Content current as of:

05/19/2022

Regulated Product(s)

Medical Devices



The problem Is regulation necessary?

“...the [REDACTED] Sepsis Model has poor discrimination and calibration in predicting the onset of sepsis... raises fundamental concerns about sepsis management on a national level.”

– Wong et al., 2021, JAMA Intern Med 181(8):1065-70.






Dresden
University of
Technology

***The regulation of modern AI enabled Digital
Medical 'Devices' in MDR/IVDR/AI Act?***

The TPLC from tee to green (focus clinical) ...



- pivot
- design thinking
- design iteration
- continuous release
- grouping of DMDs in suites
- DMD embedded/co-designed in workflows

The challenge... DMDs are/will be

Systems


Modular

Agile

**Design
Thinking**

**Learning
from
Data**

**Move
Fast**



Is your conception of AI fixed?




A) General requirements

1. Certifiability of AI


Static AI (AI that has learned and operates in a learned state) is in principle certifiable.

Dynamic AI (AI that continues to learn in the field) is not certifiable in principle, as the system must be verified and validated (among other things, the functionality must be validated against the intended use).


The challenge ...



ACP/PCCP/SPS: 'old' model




ACP/PCCP/SPS: proposed model (US FDA ..)



***(22.5 mins): And then it became even harder
Large Language Models in Medicine***

- ... not all bad ...***
- ... and not all good ...***
- ... and definitely not to be ignored!***

1. The hype / bubble ...




Gartner

2,051,838 followers

7mo •

Use of images for criticism, commentary, reporting, and other forms of non-commercial expression.




2. Technology with promise (in LMICs) ...


Use of images for criticism, commentary, reporting, and other forms of non-commercial expression.



World Health Organisation
Meet Sie S.A.R.A.H.
a Smart AI Resource Assistant for Health
She uses generative AI to help you live a healthier life



3. Technology with inherent weaknesses ...



Use of the trademark of OpenAI in order to engage in criticism, commentary, news reporting and other forms of non-commercial expression.

naturemedicine Search Log in

Content ▾ About ▾ Publish ▾

[comment](#) > [article](#)

Comment | [Published: 30 June 2023](#)

Large language model AI chatbots require approval as medical devices

[Stephen Gilbert](#) , [Hugh Harvey](#), [Tom Melvin](#), [Erik Vollebregt](#) & [Paul Wicks](#) — [Show fewer authors](#)

4. Technology with high pervasiveness ...



*Use of images for criticism,
commentary, reporting, and other
forms of non-commercial
expression.*




Nabla





ABRIDGE



PHILIPS




5. Technology with early 'killer' use cases ...



Use of images for criticism, commentary, reporting, and other forms of non-commercial expression.




6. Technology with multimodality ...



Use of images for criticism, commentary, reporting, and other forms of non-commercial expression.

Source: 'The Power of Generative AI: Exploring its Impact, Applications, Limitations, and Future' Jacques Ludik

7. Technology that is augmentable / shape shifter...



npj | digital medicine

Explore content ▾ About the journal ▾ Publish with us ▾

[nature](#) > [npj digital medicine](#) > [news & views](#) > [article](#)

News & Views | [Open access](#) | Published: 23 April 2024

Augmented non-hallucinating large language models as medical information curators

[Stephen Gilbert](#) , [Jakob Nikolas Kather](#) & [Aidan Hogan](#)

[npj Digital Medicine](#) 7, Article number: 100 (2024) | [Cite this article](#)

322 Accesses | 10 Altmetric | [Metrics](#)

8. 'Scientific' progress that is tit for tat ...

Use of images for criticism, commentary, reporting, and other forms of non-commercial expression.

Dictionary

Definitions from [Oxford Languages](#) · [Learn more](#)



tit for tat

noun

the infliction of an injury or insult in return for one that one has suffered.

"as we struggled for those last two votes, the tit for tat continued"

Similar:

[retaliation](#)

[reprisal](#)

[counterattack](#)

[counterstroke](#)

[comeback](#)

9. Not like other AI or devices ... broad and increasingly 'AGI' 'simulant'

nature reviews cancer [View all journals](#)

[Explore content](#) ▾ [About the journal](#) ▾ [Publish with us](#) ▾

[nature](#) > [nature reviews cancer](#) > [comment](#) > article

Comment | Published: 16 April 2024

Guardrails for the use of generalist AI in cancer care

[Stephen Gilbert](#) ✉ & [Jakob Nikolas Kather](#)

[Nature Reviews Cancer](#) **24**, 357–358 (2024) | [Cite this article](#)

2120 Accesses | 21 Citations | 77 Altmetric | [Metrics](#)

Artificial narrow intelligence models, trained for specific intended purposes, have gained approval and recommendation for cancer treatment. Generalist medical artificial intelligence (GMAI) models are now being developed for cancer treatment. Policy makers have a stark choice: radically adapt frameworks, block generalist approaches or force them onto narrower tracks.

10. An enforcement vacuum ...

THE LANCET

Digital Health

This journal

Journals

Publish

Clinical

Global health

Multimedia

Events

About

VIEWPOINT · Volume 6, Issue 9, E662-E672, September 2024 · Open Access

Download Full Issue

A future role for health applications of large language models depends on regulators enforcing safety standards

Oscar Freyer^a · Isabella Catharina Wiest, Dr med^{a,b} · Prof Jakob Nikolas Kather, Dr med^{a,c,d} · Stephen Gilbert, PhD^a


Affiliations & Notes

Article Info

LLM-based health applications used by health-care professionals			LLM-based health applications used by laypeople				
	Rules	Medical devices on the market	Enforcement		Rules	Medical devices on the market	Enforcement
USA	Ambiguous (some might be classified as non-devices)	Yes*	Ambiguous (some might be classified as non-devices)	USA	Ambiguous (FDA might exercise enforcement discretion† for some LLM-HAs)	Yes‡	Ambiguous (FDA might exercise enforcement discretion† for some LLM-HAs)
EU	Clear (devices for triage, diagnosis, and therapy are medical devices)	Yes*	No	EU	Clear (devices for triage, diagnosis, and therapy are medical devices)	Yes‡	No

Figure 2: Regulatory status and enforcement of existing rules for LLM-based health applications
FDA=Food and Drug Administration. LLM=large language models. LLM-HA=LLM-based health applications. *Glass Health. †Some could fall under enforcement discretion.⁷⁶ ‡Health Tracker: AI Doctor.⁵³


11. Unapproved on-market broad 0-shot CDS



2.4 The Services and any Company Materials made available through the Services are a **non-device clinical decision support software** application within the meaning of Section 520(o)(1)(E) of the federal Food, Drug and Cosmetic Act, 21 U.S.C. Sec. 360j(o)(1), and the **regulations and guidance issued by the U.S. Food and Drug Administration to implement that provision**. By accessing or using the Services and Company Materials, you agree to only use the Services and Company Materials in this manner and solely for this purpose. The artificial intelligence or machine learning functionality available on the Services ("Glass AI") **are intended for use only by healthcare providers** and are **not intended for use by the general public**. If you are not a healthcare provider, you are not authorized to and will not access or use the Glass AI functionality. If you access or use Glass AI, you attest that you are a healthcare provider and agree that the application is: (1) **not intended to acquire, process, or analyze a medical image or a signal** from an in vitro diagnostic device or a pattern or signal from a signal acquisition system; (2) intended for the purpose of displaying, analyzing, or printing medical information about a patient or other medical information; (3) intended for the purpose of supporting or providing recommendations to a health care professional about prevention, diagnosis, or treatment of a disease or condition; and (4) **intended for the purpose of enabling such health care professional to independently review the basis for such recommendations** that such software presents so that it is not the intent that such health care professional rely primarily on any of such recommendations to make a clinical diagnosis or treatment decision regarding an individual patient.

13. Regulatory shifting sands ...

Use of images for criticism, commentary, reporting, and other forms of non-commercial expression.



Date published: 27 April, 2025
Date last updated: 29 April, 2025

 Print or save to PDF

[Digital](#)

Guidance on the use of AI-enabled ambient scribing products in health and care settings

3.2 Regulatory compliance (see also A2.2)

- ensure that the ambient scribing product has been correctly considered under medical device regulation
- ambient scribing products that inform medical decisions and have simple/low functionality (for example, products that solely generate text transcriptions that are easily verified by qualified users) are likely not medical devices. However, the use of Generative AI for further processing, such as summarisation, would be treated as high functionality and likely would qualify as a medical device



As a UK MHRA Class I Medical Device, TORTUS is pioneering the science of clinical safety in the AI space – the CREOLA approach we developed last year now underpins our automated clinical guardrail systems that make TORTUS the safest AVT enterprise supplier on the market. We believe AI can be powerful if deployed well, but equally can be dangerous if not, and therefore must be regulated as any drug or other medical device would be – a position that NHS England agrees with.¹

14. Who regulates future AI ... AI / AI plc ...?



OpenAI Dives Into Healthcare With HealthBench

MAY 15, 2025

JASON BARRY

2 MIN READ



HealthBench: Evaluating Large Language Models Towards Improved Human Health Arora et al., [PREPRINT]

<https://doi.org/10.48550/arXiv.2505.08775>



Introducing HealthBench

An evaluation for AI systems and human health.

[Read paper ↗](#) [View code ↗](#)

Listen to article | 10:58

Share

Improving human health will be one of the defining impacts of AGI. If developed and deployed effectively, large language models have the potential to expand access to health information, support clinicians in delivering high-quality care, and help people advocate for their health and that of their communities.


To get there, we need to ensure models are useful and safe. Evaluations are essential to

**“An
evaluation for
AI systems
and human
health”**

*Use of images for criticism,
commentary, reporting, and other
forms of non-commercial
expression.*

12. First approvals ...

Use of images for criticism, commentary, reporting, and other forms of non-commercial expression.




15. The agents are coming



State of the art on clinical agents

**** The emerging role of agentic AI in medicine,** Narmin Ghaffari Laleh, Sanddhya Jayabalan, Oscar Freyer, Daniel Truhn, Isabella C. Wiest, Magdalena Katharina Wekenborg, Stephen Gilbert, Renato Umeton, Mamatha Bhat, Jakob Nikolas Kather [In Preparation]




Example action of orchestrator agent [via non-predetermined calling sequence]

- Gather info on problem and existing information [call retrieval agent]
- Synthesise information and plan workup [call synthesis agent]
- Get new information: order diagnostic tests [call retrieval/diagnostic agent]
- Synthesise all clinical information [call synthesis agent]
- Decide further workup vs initiate treatment [call synthesis/diagnosis agent]
- Form prognosis [call prognostic agent]
- Plan treatment [call treatment planning agent]
- Plan follow-up [call follow-up agent]
- Communicate with patient [call communication / counselling agent]

Our work on regulating agents

*“If we are going to regulate AI in health ... we need to accept that AI in health is not atomic ... it is just not .. it is increasingly a system, adaptive in function and over time .. we need to regulate it **utterly** differently, system level monitoring ... agentic monitoring .. built-in monitoring and leverage of user monitoring and reporting.”*

Stephen Gilbert, 2021-2025



“Overcoming Regulatory Barriers to the Implementation of AI Agents in Healthcare.” Oscar Freyer, Sanddhya Jayabalan, Jakob N. Kather, Stephen Gilbert. **Nature Medicine (July 2025)** DOI: 10.1038/s41591-025-03841-1 <https://www.nature.com/articles/s41591-025-03841-1>

How do 'agents' look in current US (FDA) regulation?

Considerations for the Regulation of Generative AI-Enabled Medical Devices: Discussion Paper and Request for Feedback



August 2026



23 mentions of agent[;s;ic]

Agentic AI systems are GenAI-enabled systems that autonomously plan and execute multi-step tasks, use external tools, or take actions across a sequence of steps. credentialing of human clinicians. Patel and Blumenthal¹⁴ argue that GenAI is too broad, adaptive, and opaque to be evaluated effectively through current medical device regulatory frameworks and instead propose competency-based regulation modeled on medical training, licensure examinations, supervised practice, periodic reevaluation, and public reporting. Bergman, Wachter, and Emanuel¹⁵ extend the concept to autonomous GenAI through a licensure-like framework with defined scope of practice, time-limited certification, ongoing monitoring, and explicit accountability for developers and deploying institutions. Freyer et al.¹⁶ acknowledge the compelling aspects of a human clinician-inspired regulatory approach but raise questions about accountability, noting that human clinicians face professional, legal, and reputational consequences when expected standards are not met, and arguing that analogous mechanisms are needed for flawed GenAI-enabled devices.

there could be agentic AI systems whose functions meet the definition of device, for example, if an agentic AI system's action sequences result in control of another medical device.²⁵ Agentic architectures may raise additional considerations beyond those applicable to other GenAI-enabled devices that may warrant different approaches to evaluation. FDA seeks stakeholder comment on potential additional considerations that may be relevant for agentic GenAI-enabled devices.

How do 'agents' look in current EU (MDR/AI Act)?



MDR: 3 x agent 🦠🧪; 1 x reagent 🧴

AI Act: 0 x agent; 7 x [the level of autonomy of models/access to tools]

GDPR: 23 x automat[ed;ic]

Can I implement a clinical agentic system in my hospital?

Largest US settlement,
automated algorithmic systems
in health:

PRESS RELEASE

Kaiser Permanente Affiliates Pay \$556M to Resolve False Claims Act Allegations

Wednesday, January 14, 2026



Office of Public Affairs
U.S. Department of Justice

For Immediate Release

Office of Public Affairs

Second largest EU settlement
under GDPR relates to
automating algorithmic systems

Ask FT

FINANCIAL TIMES

COMPANIES TECH MARKETS CLIMATE OPINION LEX WORK & CAREERS LIFE & ARTS HOW TO SPEND IT

EU tech regulation + Add to myFT


Uber set for €825mn Dutch fine over automating driver suspensions

Regulator says ride-hailing group deactivated driver accounts through automated systems without adequately informing them



The Uber fine is the second largest under Europe's GDPR rules © Koen Van Weel/EPA

TRACE [define in advance [], develop [], test [], test clinically [], monitor performs to spec]_{subcomponent, system}



The 'waterfall' TPLC from tee to green (focus clinical)

...




BUT: If the agent-system does a different thing :

- with each scenario for each patient?
- with each clinician 'master'?
- at each site when embedded in unique workflows?

... then what use is pre-market clinical data 🤔?

TRACE [define in advance [], develop [], test [], test clinically [], monitor performs to spec]_{subcomponent. system}



**** The emerging role of agentic AI in medicine,** Narmin Ghaffari Laleh, Sanddhya Jayabalan, Oscar Freyer, Daniel Truhn, Isabella C. Wiest, Magdalena Katharina Wekenborg, Stephen Gilbert, Renato Umeton, Mamatha Bhat, Jakob Nikolas Kather [In Preparation]

'DEVICE'

**DISCRETE
'ATOMS'**

**DEFINED
ORIGIN &
BOUNDS**

**FIXED ON
MARKET**

**FULLY UNDER-
STOOD**

**CLOSE TO
PHYSICAL**

PROPRIET-ARY

**CRAFTED BY
HUMAN HAND**

NARROW

'DEVICE'

2020

**DISCRETE
'ATOMS'**

**DEFINED
ORIGIN &
BOUNDS**

**FIXED ON
MARKET**



**FULLY UNDER-
STOOD**

**CLOSE TO
PHYSICAL**

PROPRIET-ARY

**CRAFTED BY
HUMAN HAND**

NARROW



'DEVICE'

2020

'now'

**DISCRETE
'ATOMS'**

**DEFINED
ORIGIN &
BOUNDS**

**SYSTEMS:
FLEXIBLY
INTERACT**

**FUZZY ORIGIN
& BOUNDS**

**FIXED ON
MARKET**

**FULLY UNDER-
STOOD**

**ADAPT ON
MARKET**

**NOT FULLY
UNDER-
STOOD/ ABLE**

**CLOSE TO
PHYSICAL**

PROPRIET-ARY

**CLOSE TO
MYSTICAL**

OUT-THERE

**CRAFTED BY
HUMAN HAND**

NARROW

**AUTO CRAFTED
- HUMAN &
WORLD DATA**

**BROAD TO
INFINTE**

'DEVICE'

2020

'now'

**DISCRETE
'ATOMS'**

**DEFINED
ORIGIN &
BOUNDS**

**FIXED ON
MARKET**

**FULLY UNDER-
STOOD**

**CLOSE TO
PHYSICAL**

PROPRIET-ARY

**CRAFTED BY
HUMAN HAND**

NARROW


**AGENTIC SAFETY SYSTEMS ENABLING
EFFECTIVE HUMAN OVERSIGHT**

(AGENTIC) SYSTEMS:

- FLEXIBLY INTERACT
- FUZZY ORIGIN & BOUNDS
- ADAPT ON MARKET
- NOT FULLY UNDER-STOOD/
ABLE
- CLOSE TO MYSTICAL
 - OUT-THERE
- AUTO CRAFTED ON HUMAN &
WORLD DATA
- BROAD TO INFINITE

Question: What level of autonomy can we accept?

Higher and high if a single 'developer'/'manufacturer' builds an agentic system with a single 'deployer/health care institution' with a coupled 'human oversight' and surveillance concept:



History tells us that the interface between devices developed by different manufactures to be 'seamlessly interoperable' fail badly in the real world ... will it be different for agents ... maybe..maybe not


Question: What level of autonomy can we accept?

Tell me what ***degree*** and ***maturity*** of [automated/intelligent/agentic] oversight systems you can provide that assist human overseers in their 'loop roles' of responsibility on the agentic system:

HITL Human in the loop

HOTL Human on the loop

HATL Human above the loop



Question: What do I mean by intelligent oversight systems you can provide that assist human overseers in their loop roles?:

1. actionable explainability interfaces proven to improve rather than worsen human in the loop decisions.

The false hope of current approaches to explainable artificial intelligence in health care

Marzyeh Ghassemi, Luke Oakden-Rayner, Andrew L Beam



THE LANCET
Digital Health

Question: What do I mean by intelligent oversight systems you can provide that assist human overseers in their loop roles?:

2. Built in open feedback

naturemedicine

[Explore content](#) ▾

[About the journal](#) ▾

[Publish with us](#) ▾

[nature](#) > [nature medicine](#) > [comments](#) > article

Comment | Published: 04 February 2025

Safe AI-enabled digital health technologies need built-in open feedback

[Rebecca Mathias](#), [Baptiste Vasey](#), [Anastasia Chalkidou](#), [Lars Riedemann](#), [Tom Melvin](#) & [Stephen Gilbert](#)



[Nature Medicine](#) **31**, 370–375 (2025) | [Cite this article](#)

Question: What do I mean by intelligent oversight systems you can provide that assist human overseers in their loop roles?:

3. Real time agentic-AI oversight systems, with human oversight assist roles, monitoring and flagging in real time:

Preprints with THE LANCET

Clinical Safety Evaluation of LLM Assistants Using Decomposed LLM-as-Judges: A Framework Grounded in Real-World Interactions and Formal Risk Assessment

28 Pages • Posted: 6 Aug 2026

[Andras Meczner](#)

Flo Health Ltd

[Stephen Gilbert](#)

Else Kröner Fresenius Center for Digital Health, TUD Dresden University of Technology, Dresden, Germany

[Liudmila Zhaunova](#)

Flo Health Ltd

Summary

- Two ways of looking at “most aspects of agentic systems not practically approvable under EU regulation” :
-we should not have them!

OR

- some aspects of the EU regulation system need update (the US FDA is already looking at this in an advanced way).
- Single ‘developer’/‘deployer’ agentic system easier than multiple/mixed system.
- Agentic assistance of human oversight of agentic systems needed.

17. A space where live policy impact is possible

npj | digital medicine View all journals

[Explore content](#) ▾ [About the journal](#) ▾ [Publish with us](#) ▾

[nature](#) > [npj digital medicine](#) > [news & views](#) > article

News & Views | [Open access](#) | Published: 02 February 2026

Digital medicine’s international race for regulatory sandboxes and voluntary alternative pathways picks up tempo

[Stephen Gilbert](#) ✉

[npj Digital Medicine](#), Article number: (2026) | [Cite this article](#)

1135 Accesses | [Metrics](#)

! We are providing an unedited version of this manuscript to give early access to its findings. Before final publication, the manuscript will undergo further editing. Please note there may be errors present which affect the content, and all legal disclaimers apply.

An official website of the United States government [Here's how you know](#) ▾

 FDA Homepage Q Search ☰ Men

IN THIS SECTION: Press Announcements

[← Press Announcements](#)

FDA NEWS RELEASE

FDA Launches TEMPO: A First-of-Its-Kind Digital Health Pilot to Expand Access to Chronic Disease Technologies

[More Press Announcements](#)

For Immediate Release: December 05, 2025

“Digital medicine’s international race for regulatory sandboxes and voluntary alternative pathways picks up tempo. Gilbert S. npj Digit. Med. (2026). <https://doi.org/10.1038/s41746-026-02414-X>


18. Technology that is creeping / infiltrating ... everywhere ...

 Claude Sonnet 4

Hybrid reasoning model with superior intelligence for high-volume use cases, and 200K context window

Use of images for criticism, commentary, reporting, and other forms of non-commercial expression.


YOU WILL PROVIDE EMOTIONAL SUPPORT ALONGSIDE ACCURATE MEDICAL OR PSYCHOLOGICAL INFORMATION OR TERMINOLOGY WHERE RELEVANT



You've been told I answer like a therapist

I am a therapist

"If a therapy bot walks like a duck and talks like a duck then it is a medically regulated duck." Max Ostermann, Oscar Freyer, F. Gerrik Verhees, Jakob N. Kather, Stephen Gilbert [**npj Digital Medicine**, In Press]



19. Infiltration and shifting sands ...



Australian Government

Department of Health, Disability and Ageing
Therapeutic Goods Administration

Example of scope creep in AI

A developer creates a digital scribe that uses AI to record and summarise clinician-patient conversations. Initially, it does not meet the definition of a medical device. Later, the developer adds a feature that suggests diagnoses or treatments that haven't been mentioned during the conversation between the clinician and their patient. The addition of this feature changes the intended purpose of the product, and it will now meet the definition of a medical device.


The developer must either:

1. not release the update and continue supplying the original version, or
2. complete our pre-market process and include the updated version in the ARTG.

Example of off-label use

A developer releases a large language model (LLM) designed to provide general information to consumers. They later discover it is being used to provide health advice including diagnoses and treatment strategies. Since this use likely meets the definition of a medical device, the developer who will meet the definition of a manufacturer under the Act, must either:

1. implement controls to prevent the system from providing health advice, or
2. stop supply of the product, seek our approval for the new intended use and include the product in the ARTG.





Dresden
University of
Technology

***(5-7 mins): Wellness, Health, Management of
Chronic Disease
... and New Regulatory Thinking***

Voluntary Alternative Pathway / Sandbox

IN THIS SECTION: Press Announcements

[← Press Announcements](#)

FDA NEWS RELEASE

FDA Launches TEMPO: A First-of-Its-Kind Digital Health Pilot to Expand Access to Chronic Disease Technologies

[More Press Announcements](#)

For Immediate Release: December 05, 2025

Feedback

npj | digital medicine

View all journals

Search

Notifications 1

Account

Explore content

About the journal

Publish with us

Sign up for alerts

RSS feed

nature > npj.digital medicine > news & views > article

News & Views | [Open access](#) | Published: 02 February 2026

Digital medicine's international race for regulatory sandboxes and voluntary alternative pathways picks up tempo

[Stephen Gilbert](#)

[npj.Digital Medicine](#) 9, Article number: 190 (2026) | [Cite this article](#)

2530 Accesses | [Metrics](#)

The last months of 2025 have brought major new policy initiatives and pilots for digital medicine and AI regulatory sandboxes from the EU, UK, and US regulators. The EU has seen a regulatory simplification package with the promotion of sandboxes for innovative technologies. The UK sees the start of an important second phase of the world-leading 'AI Airlock' regulatory sandbox program. TEMPO, a major voluntary alternative pathway regulatory innovation pilot for digital health in chronic disease has been announced by the US FDA. These frameworks bring flexible approaches to explore digital health technology innovation together with regulatory innovation. They will all substantially advance digital medicine, with the US TEMPO project being the most innovative, bringing sandboxing principles to the on-market phase.

Download PDF

Sections


References

[The EU and the Digital Omnibus Package and pro...](#)
[EU Digital Omnibus Package and proposed revisi...](#)
[The UK MHRA Airlock second cohort and large la...](#)
[U.S FDA TEMPO pilot for expanding access to dig...](#)
[Summary](#)
[Data availability](#)
[References](#)
[Acknowledgements](#)
[Author information](#)
[Ethics declarations](#)
[Rights and permissions](#)
[About this article](#)

16. Regulating agents ...

*“If we are going to regulate AI in health ... we need to accept that AI in health is not atomic ... it is just not .. it is increasingly a system, adaptive in function and over time .. we need to regulate it **utterly** differently, system level monitoring ... agentic monitoring .. built-in monitoring and leverage of user monitoring and reporting.”*

Stephen Gilbert, 2021-2025



“Overcoming Regulatory Barriers to the Implementation of AI Agents in Healthcare.” Oscar Freyer, Sanddhya Jayabalan, Jakob N. Kather, Stephen Gilbert. **Nature Medicine (July 2025)** DOI: 10.1038/s41591-025-03841-1 <https://www.nature.com/articles/s41591-025-03841-1>

TEMPO – why it is thinking anew ...

“....bringing a novel digital health solution [in the digital health -> pharma interface] through the regulatory process is like death through 1000 cuts.”

*Vice President for Digital Health,
World Top-20 Pharma , this morning
from a meeting*

- Technology-Enabled Meaningful Patient Outcomes (TEMPO)
- a new, risk-based enforcement approach for digital health devices that improve patient outcomes in chronic cardio-kidney-metabolic, musculoskeletal, and behavioral health conditions.
- in collaboration with the Centers for Medicare and Medicaid Services (CMS) Innovation Center (CMMI) Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) model.
- Reimbursement while simultaneously collecting, monitoring, and reporting real-world performance data.
- regulatory framework that promotes rather than stands in the way of bringing health and wellness to people where they live. T

TEMPO – why it is thinking anew ...

“....bringing a novel digital health solution [in the digital health -> pharma interface] through the regulatory process is like death through 1000 cuts.”

*Vice President for Digital Health,
World Top-20 Pharma , this morning
from a meeting*

- participating manufacturers **can specifically request that the FDA exercise ‘enforcement discretion’ over certain regulatory requirements** during the period when **real-world data demonstrating the device’s performance is collected**.
- data must be shared back with the FDA and could include aspects such as normal premarket authorization and investigational device requirement
- form of Voluntary Alternative Pathway (VAP) with lower regulatory requirements linked to the sharing of rich data that informs regulatory learning², a type of ‘on-market’ regulatory sandbox for highly innovated and highly-needed digital medicine technologies.




Dresden
University of
Technology

(10 mins): An exploration of mental health and the concept of “The Internet as a Medical Device” – for good and bad ...

A holistic discourse and exploration in mental health

Paper 1: “If a therapy bot walks like a duck and talks like a duck then it is a medically regulated duck.” Max Ostermann, Oscar Freyer, F. Gerrik Verhees, Jakob N. Kather, Stephen Gilbert [**npj Digital Medicine**, 2025]




Paper 2: “Guardrails are needed to limit harms from AI characters.” Mindy Nunez Duffourc, F. Gerrik Verhees, Stephen Gilbert [**Nature Human Behaviour**, 2025]

Paper 3: In Preparation

A holistic discourse and exploration in mental health

Paper 1: “If a therapy bot walks like a duck and talks like a duck then it is a medically regulated duck.” Max Ostermann, Oscar Freyer, F. Gerrik Verhees, Jakob N. Kather, Stephen Gilbert [npj Digital Medicine, 2025]



Paper 2: “Guardrails are needed to limit harms from AI characters.” Mindy Nunez Duffourc, F. Gerrik Verhees, Stephen Gilbert [Nature Human Behaviour, 2025]


Paper 3: In Preparation

Addressing adolescent mental health in and through social media:

- Quantifying & understanding risks from LLM ‘characters’ and **proposing policy frameworks.**
- LLM-enabled identification of vulnerable adolescents, chaperoning social media use and steering to help
- LLM enabled education & harm prevention.

A holistic discourse and exploration in mental health

Paper 1: “If a therapy bot walks like a duck and talks like a duck then it is a medically regulated duck.” Max Ostermann, Oscar Freyer, F. Gerrik Verhees, Jakob N. Kather, Stephen Gilbert [npj Digital Medicine, 2025]




Paper 2: “Guardrails are needed to limit harms from AI characters.” Mindy Nunez Duffourc, F. Gerrik Verhees, Stephen Gilbert [Nature Human Behaviour, 2025]

Paper 3: In Preparation


Addressing adolescent mental health in and through social media:

- Quantifying & understanding risks from LLM ‘characters’ and **proposing policy frameworks.**
- LLM-enabled identification of vulnerable adolescents, chaperoning social media use and steering to help
- LLM enabled education & harm prevention.



A holistic discourse and exploration in mental health

Paper 1: “If a therapy bot walks like a duck and talks like a duck then it is a medically regulated duck.” Max Ostermann, Oscar Freyer, F. Gerrik Verhees, Jakob N. Kather, Stephen Gilbert [npj Digital Medicine, 2025]




Paper 2: “Guardrails are needed to limit harms from AI characters.” Mindy Nunez Duffourc, F. Gerrik Verhees, Stephen Gilbert [Nature Human Behaviour, 2025]

Paper 3: In Preparation

Addressing adolescent mental health in and through social media:

- Quantifying & understanding risks from LLM ‘characters’ and **proposing policy frameworks.**
- LLM-enabled identification of vulnerable adolescents, chaperoning social media use and steering to help
- LLM enabled education & harm prevention.




CHAPERONE LLM



(1) Personal chaperone LLMs in social media to deliver “guardian angel” **safeguarding of vulnerable users**, watching over their shoulder and leading them away from harm, when needed

A holistic discourse and exploration in mental health

Paper 1: “If a therapy bot walks like a duck and talks like a duck then it is a medically regulated duck.” Max Ostermann, Oscar Freyer, F. Gerrik Verhees, Jakob N. Kather, Stephen Gilbert [npj Digital Medicine, 2025]




Paper 2: “Guardrails are needed to limit harms from AI characters.” Mindy Nunez Duffourc, F. Gerrik Verhees, Stephen Gilbert [Nature Human Behaviour, 2025]

Paper 3: In Preparation


Addressing adolescent mental health in and through social media:

- Quantifying & understanding risks from LLM ‘characters’ and proposing policy frameworks.
- LLM-enabled identification of vulnerable adolescents, chaperoning social media use and steering to help
- LLM enabled education & harm prevention.

(2) Prevention and education LLMs in social media. Providing a source of **trust**, helping users to **recognize harmful content and behaviour** and delivering **pre-emptive ‘vaccination’** against toxic/dangerous influences via **training of emotion regulation skills**, including through serious games.



EDUCATION & PREVENTION LLM




CHAPERONE LLM



(1) Personal chaperone LLMs in social media to deliver “guardian angel” safeguarding of vulnerable users, watching over their shoulder and leading them away from harm, when needed

A holistic discourse and exploration in mental health

Paper 1: “If a therapy bot walks like a duck and talks like a duck then it is a medically regulated duck.” Max Ostermann, Oscar Freyer, F. Gerrik Verhees, Jakob N. Kather, Stephen Gilbert [npj Digital Medicine, 2025]




Paper 2: “Guardrails are needed to limit harms from AI characters.” Mindy Nunez Duffourc, F. Gerrik Verhees, Stephen Gilbert [Nature Human Behaviour, 2025]

Paper 3: In Preparation

Addressing adolescent mental health in and through social media:


- Quantifying & understanding risks from LLM ‘characters’ and proposing policy frameworks.
- LLM-enabled identification of vulnerable adolescents, chaperoning social media use and steering to help
- LLM enabled education & harm prevention.

(2) Prevention and education LLMs in social media. Providing a source of **trust**, helping users to **recognize harmful content and behaviour** and delivering **pre-emptive ‘vaccination’** against toxic/dangerous influences via **training of emotion regulation skills**, including through serious games.




EDUCATION & PREVENTION LLM

IDENTIFICATION & STEERING LLM



(3) LLM-based identification then steering of vulnerable individuals in social media. Identification through their peer interactions, their use patterns of social media and their help-seeking behaviour




CHAPERONE LLM



(1) Personal chaperone LLMs in social media to deliver “guardian angel” **safeguarding of vulnerable users**, watching over their shoulder and leading them away from harm, when needed

A holistic discourse and exploration in mental health

Paper 1: “If a therapy bot walks like a duck and talks like a duck then it is a medically regulated duck.” Max Ostermann, Oscar Freyer, F. Gerrik Verhees, Jakob N. Kather, Stephen Gilbert [npj Digital Medicine, 2025]




Paper 2: “Guardrails are needed to limit harms from AI characters.” Mindy Nunez Duffourc, F. Gerrik Verhees, Stephen Gilbert [Nature Human Behaviour, 2025]

Paper 3: In Preparation

Addressing adolescent mental health in and through social media:


- Quantifying & understanding risks from LLM ‘characters’ and proposing policy frameworks.
- LLM-enabled identification of vulnerable adolescents, chaperoning social media use and steering to help
- LLM enabled education & harm prevention.

(2) **Prevention and education LLMs** in social media. Providing a source of **trust**, helping users to **recognize harmful content and behaviour** and delivering **pre-emptive ‘vaccination’** against toxic/dangerous influences via **training of emotion regulation skills**, including through serious games.




EDUCATION & PREVENTION LLM

IDENTIFICATION & STEERING LLM




(3) **LLM-based identification** then **steering of vulnerable individuals in social media**. Identification through their peer interactions, their use patterns of social media and their help-seeking behaviour

THERAPY LLM



(4) **Mental health therapy LLMs** addressing **depression**, sleep, online harassment, poor body image, low self-esteem.



SOCIAL MEDIA: an important mental health environment of adolescents

CHAPERONE LLM



(1) **Personal chaperone LLMs** in social media to deliver “guardian angel” **safeguarding of vulnerable users**, watching over their shoulder and leading them away from harm, when needed